The antibody is already approved to treat plaque psoriasis, psoriatic arthritis and, since last September, in ulcerative colitis, achieving sales of almost $3.7 billion last year, but J&J has said ...

Once-daily oral IL-23 inhibitor icotrokinra (formerly JNJ-2113) – which J&J licensed from Protagonist Therapeutics in 2017 – hit both its main efficacy objectives in the ICONIC-LEAD trial ...

The move would create a new consumer health company within 18 to 24 months, according to J&J, which said it would unlock "significant value" whilst allowing the company to focus on its faster ...

J&J's drug features a silicone-based drug delivery system that allows for the continuous release of gemcitabine chemotherapy and is administered into the bladder via a catheter. The FDA has ...

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the market – but J&J thinks the broad label for Imaavy (nipocalimab ...

J&J acquired rights to the silicone-based drug delivery device used in TAR-200, which allows for the continuous release of medication to the bladder, when it bought privately-owned biotech Taris ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

J&J Snack Foods Corp. manufactures, markets, and distributes nutritional snack food and beverages to the food service and retail supermarket industries in the United States, Mexico, and Canada.

The US regulator has turned down J&J's marketing application for a subcutaneous (SC) formulation of EGFRxMET bispecific antibody Rybrevant (amivantamab) – used to treat non-small cell lung ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

David J. Lynch joined The Washington Post in November 2017 from the Financial Times, where he covered white-collar crime. He was previously the cybersecurity editor at Politico and a senior writer ...